Christopher Bunka, CEO, 10% Owner at Lexaria Bioscience Corp. (LXRP), bought 62,305 shares at $0.10 ($7K) on 2016-07-14, disclosed to the SEC on 2016-07-15.
Open-market purchase of $7k LXRP by CEO, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.10 | 8,800 | $880 | 11.8% |
| 2 | $0.14 | 5,000 | $675 | 9.1% |
| 3 | $0.11 | 7,000 | $770 | 10.3% |
| 4 | $0.12 | 6,000 | $716 | 9.6% |
| 5 | $0.12 | 5,105 | $610 | 8.2% |
| 6 | $0.12 | 7,400 |
| $884 |
| 11.9% |
| 7 | $0.12 | 10,000 | $1K | 16.1% |
| 8 | $0.13 | 8,000 | $1K | 14.0% |
| 9 | $0.14 | 5,000 | $675 | 9.1% |
| Total | $0.12 avg | 62,305 | $7K | 100% |
| Filing → |
| LXRP | BUY | 2016-08-18 | $2K | — | Filing → |
| LXRP | BUY | 2016-01-12 | $4K | — | Filing → |